Previous studies had shown that a combination treatment of TRAIL and conventional dose cisplatin (>7.5 μg/ml) was effective in some tumor cells (26, 27), but few studies on TRAIL combined with subtoxic-dose cisplatin were reported in NSCLC cells, and its underling mechanism was also not well understood. The gene discussed is TNFSF10; the disease is neoplasm.